Top Markets
#1 Seeker Seeker +146.01%
#2 MowCat MowCat +109.02%
#3 AI XOVIA AI XOVIA +103.40%
#4 Helium Helium +97.25%
#5 Pons Pons +43.39%
#6 UnifAI Network UnifAI Network +33.44%
#7 Zora Zora +30.95%
#8 Bounce Bounce +22.78%
#9 Zylo Ecosystem Zylo Ecosystem +22.03%
#10 pipedog pipedog +15.70%
Coin of the day
Seeker Seeker
Settings
Language
ENGLISH
Currency
USD
Theme
Jacobio Pharmaceuticals Group Co., Ltd. Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

1167
Rank in Stocks #11796
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm... Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Share Price
$0.84111496
Last synced: 2026-08-28
Market Cap
$657.90M
Change (1 day)
-0.75%
Change (1 year)
-19.13%
Country
CN
Trade Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Category

Healthcare
Revenue for Jacobio Pharmaceuticals Group Co., Ltd. (1167)
Revenue in Aug 2026 TTM: 0
According to Jacobio Pharmaceuticals Group Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jacobio Pharmaceuticals Group Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH